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http:WHAT THIS PAPER ADDS
Infection of an aortic graft is a rare but catastrophic condition. There is very little data on management with graft
retention. This study documents short and medium term outcomes of a cohort of patients managed primarily
with antimicrobial therapy and surgery aimed at draining pus and preventing haemorrhage.Objective: To document the treatment of all patients with infected aortic grafts at Christchurch Hospital between
1999 and 2010, focussing on the mortality and morbidity of those treated without graft explantation.
Methods: Cases of infected aortic grafts were reviewed. Cases required a compatible clinical syndrome, CT
imaging and tissue/blood culture results.
Results: Eighteen patients were identiﬁed. Organisms isolated at diagnosis from blood or graft site were
Staphylococcus aureus 6 (MRSA 1), beta haemolytic streptococci 2, enteric organisms 9.Therewas no isolate from2.
One case had graft explantation and brief antimicrobial therapy. Seventeen patients had the graft retained. Of
these, 14 received intravenous antimicrobial therapy for 6 weeks and 14 lifelong oral therapy. None died during
their initial admission or within 30 days. During a mean follow-up of 57 months, 10 (59%) relapsed (median time
31 months, range 0e98), 4 (24%) underwent graft explantation and 10 (59%) died (median 40 months, range 1e
198). Four of 10 who relapsed had organisms isolated (all enteric).
Conclusion: Patients treated with lifelong antimicrobial therapy and graft retention survived a median of 41
months, with low early mortality although over half relapsed. Empiric therapy should cover skin organisms and
enteric organisms, even for those outside the post-operative period.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved
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Infection complicates 1e2% of abdominal aortic vascular
grafts, and often has a devastating outcome.1 Partially
because of the low rates of infection the preferred treat-
ment and long-term outcome have not been well deﬁned.
Curative surgical intervention is regarded as the primary
treatment modality with complete graft excision and local
debridement with in-situ reconstruction offering the best
approach.2 The inpatient mortality for this surgical inter-
vention is between 13% and 25% in published series, with
recurrent infection rates among survivors of over 20%.3e7rresponding author. Tel.: þ64 3 3640 951; fax: þ64 3 3640952.
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//dx.doi.org/10.1016/j.ejvs.2013.01.019In patients deemed unsuitable for curative operative
management due to either medical co-morbidities or
a hostile abdomen, treatment with antibiotics and evacua-
tion of infected material is recommended. The concept of
lesser surgery, with graft retention and systemic and local
antibiotic therapy has been reported in small series.4,8e10
These reports have shown that graft retention can be asso-
ciatedwith long-term survival but there is a paucity of data to
guide recommendations for antibiotic treatment.11,12
This study examines the treatment and outcome of
patients with infected aortic grafts at Christchurch Hospital,
New Zealand between 1999 and 2010, and describes the
mortality rate of those treated without complete excision of
the infected graft and the morbidity of this approach.METHOD
The study was a retrospective single institution audit per-
formed at Christchurch Hospital, a tertiary care facility
providing the only acute vascular surgical service for the
region of 500,000 people and was exempt from review by
Table 1. Baseline patient characteristics.
Number 18
Age (mean) 71 years
(range 48e85)
Gender Male:Female 16:2
Co-morbidities Chronic obstructive
pulmonary disease
8
Myocardial infarction 7
Cancer 4
Diabetes mellitus 2
Indication for
insertion
Aneurysm 11
Occlusive disease 6
Malignancy 1
Graft type Aorto bifemoral 7
Aorto bi-iliac 6
Tube 5
Table 2. Characteristics of the aortic graft infection.
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cases of infected abdominal aortic grafts between January
1999 and December 2010 were reviewed. Cases were
identiﬁed using an internal departmental database of
patients. This was cross-referenced with a computerised
search of the hospital database for ICD 10 codes T827 and
Y832 to ensure all cases were identiﬁed.
Caseswere included if theymet the following criteria: fever
and/or an inﬂammatory reaction as well as: (a) isolation of
a microorganism from the aortic graft material or tissue
connected directly to the infected graft site; or (b) compu-
terised tomography (CT) showing a perigraft collection, with
or without gas; or (c) identiﬁcation of a microorganism from
blood culture together with CT imaging features consistent
with graft infection. Consistent CT features were deﬁned as
ectopic gas, perigraft ﬂuid collection, pseudoaneurysm
formation, perigraft soft tissue (>5 mm) mass which may be
associated with hydronephrosis or adjacent osteomyelitis.
Early post-operative infection was deﬁned as within 4
months of graft insertion.12
The location of infection is recorded according to the
Bunt classiﬁcation which divides infections into intracavitary
or limited to the femoral/iliac component alone.13
Primary endpoints were death and limb amputation. The
secondary endpoint was relapse which was a composite of
an infective episode relating to the aortic graft that required
a change in treatment, or a vascular graft complication due
to infection; including sinus formation, aorto-enteric ﬁstula,
thrombosis or rupture.
Data were collected onto a standardised reporting form
covering patient demographics, co-morbidities, mortality,
description of any operative procedure, reason for non-
operative strategy, causative organisms identiﬁed, detail of
antimicrobial strategy, relapses, inpatient days during initial
and subsequent related admissions and complications of
therapy. The antimicrobial therapy administered and
monitoring investigations were collected prospectively and
additional data was collected retrospectively from the
hospital notes. All diagnostic imaging was reviewed by
a vascular radiologist (TB). The data was entered into an
EXCEL database for analysis. The survival analysis for the
Kaplan Meier survival curve was performed in R 2.14.0.14Location of
Infection
Intracavitary (Bunt P0) 15
Iliac/femoral component alone (Bunt P1) 3
Timing of
infection
Early (<4 months) 3
Late (>4 months) 15
Presenting
feature
Fever  abdominal pain 10
Wound infection, false aneurysm or sinus 6
Septic emboli 1
Aorto-enteric ﬁstula 1
Diagnosis Positive tissue cultures from perigraft
tissue or ﬂuid
10
Positive blood culture in conjunction with
CT imaging
6
Perigraft collection with appropriate
clinical syndrome
2RESULTS
Twenty-three patients were treated for an infected aortic
graft over the time period and 18 had sufﬁcient evidence of
infection to meet the study deﬁnition. Demographic details,
co-morbidities, indication for graft insertion and graft type
are shown in Table 1. Characteristics of the graft infection are
presented in Table 2. Most patients presented with systemic
(11/18) or local (6/18) symptoms relating to infection. Aorto-
enteric ﬁstula was an uncommon presenting problem (1/18).
Organisms were isolated from the graft site (percutane-
ously or at operation) of 10 patients during their presenting
illness and from the blood in a further 6. These included 7
isolates that predominantly reside on the skin and/or
pharynx (Staphylococcus aureus, and Streptococcuspyogenes) and 9 enteric aerobic or anaerobic species
(Table 3). Six cases were polymicrobial. Of those diagnosed
within 4 months of graft insertion, S. aureus was isolated
from 2 and mixed enteric organisms from 1 patient.
One patient underwent complete excision of an end to
side aortic graft as initial management. Collateral circulation
made aortic patency unnecessary, but aortoplasty with
a small rifampicin soaked patch was performed. He was
treated with 3 days of intravenous amoxicillineclavulanate
and 7 days of oral amoxicillineclavulanate. Pseudomonas
aeruginosa, resistant to amoxicillineclavulanate, was iso-
lated from the graft site. Despite antimicrobial therapy not
active against the isolate, he made an uncomplicated
recovery and remained well for 12 months. He was
admitted 13 months later with viridans streptococcal sepsis
due to infection at the site of the dacron patch. The dacron
patch was removed, and 6 weeks of intravenous piper-
acillinetazobactam and oral ciproﬂoxacin were adminis-
tered followed by lifelong treatment with oral ciproﬂoxacin.
He had no further re-admissions associated with the aortic
infection and remains alive 128 months after diagnosis.
Seventeen patients were treated with antimicrobial
therapy and retention of the graft. Conservative manage-
ment was chosen after consideration of the operative risks,
Table 3. Organisms isolated from the infected graft, tissues
adjacent to the graft or blood.
Organisms At diagnosis At relapse
Staphylococcus aureus 6 (1 MRSA) 0
Streptococcus pyogenes 1 0
Group B Streptococci 1 0
Viridans Streptococci 4 1
Enterococcus faecalis 0 2
Enterococcus faecium 0 2
Enterococcus gallinarum 0 1
Anaerobic Streptococci 2 0
Escherichia coli 2 0
Klebsiella oxytoca 1 0
Pseudomonas aeruginosa 1 2
Mixed coliform bacilli (not
identiﬁed further)
1 0
Fusobacterium necrophorum 1 0
Baceroides fragilis 1 0
Lactobacilli casei/rhamnosus 0 1
Candida albicans 0 2
MRSA ¼ Methicillin resistant S. aureus.
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difﬁculties and patient preference. The operative procedures
performed are shown in Table 4. Percutaneous drainage was
performed under radiological guidance. Irrigation of the
perigraft abscess cavity was not performed in any patient.
All patients managed with graft retention received
intravenous antimicrobial therapy (cephalosporins 8, peni-
cillins 5, carbapenem 3, glycopeptide 1 and 5 additional
metronidazole) of whom 14 were treated for 6 weeks, 1 for
4 weeks and 2 for 2 weeks. Antimicrobial therapy prior to
the diagnosis of the infection was not recorded. Of those
treated for fewer than 6 weeks, 1 died while still onTable 4. Interventions performed at initial presentation or relapse
on 18 patients with abdominal aortic graft infection.
Initial procedural
intervention
Follow-up procedural
intervention
Median
survival/
Follow-up
Non-operative
management
n ¼ 9
Nil 7 40 months
(1/7 alive)
Complete excision
(1 with anatomic
and 1 with extra-
anatomic bypass)
2 10 months
(0/2 alive)
Drainage
n ¼ 7
Nil 4 48.5 months
(3/4 alive)
Extra-anatomic
bypass and graft
retention
1 65 months
(alive)
Percutaneous
drainage
1 165 months
(alive)
Complete excision
& anatomic
bypass
1 98 months
(dead)
Anatomic bypass
and aneurysm
repair n ¼ 1
Complete excision
& extra-anatomic bypass
1 22 months
(alive)
Complete excision
n ¼ 1
Removal of dacron patch 1 128 months
(alive)intravenous antimicrobials (at 31 days) and 2 were stopped
before 6 weeks due to rapid clinical improvement. Four of
seven patients infected with S. aureus or beta haemolytic
streptococci were treated with oral rifampicin in addition to
the intravenous therapy. Fourteen patients subsequently
received lifelong oral antimicrobial therapy that was active
against the relevant bacterial isolates (amoxicillineclav-
ulanate 6, amoxicillineclavulanate/ciproﬂoxacin 3, ﬂuclox-
acillin 3, fusidic acid/ciproﬂoxacin 1, and penicillin VK 1). Of
the 4 who were not treated with lifelong antimicrobials, 2
were infected with S. aureus and were treated with 6 weeks
intravenous ﬂucloxacillin and oral rifampicin followed by 6
weeks of oral therapy including rifampicin. The other 2 were
infected with enteric organisms and were treated with 2
and 6 weeks intravenous therapy followed by 4 and 6 weeks
oral therapy respectively. The antimicrobials in these
patients were stopped with the expectation of cure,
although 1 of 2 in each group subsequently relapsed.
No patients died during their initial admission, or within
30 days of diagnosis. Ten patients (59%) died during the
follow-up period, at a median of 40.5 months (range 1e98).
Six of these deaths were attributed to the aortic graft
infection, 3 due to ischaemic heart disease and 1 due to
malignancy. Survival data is plotted on the Kaplan Meier
graph (Fig. 1). This includes all patients, including those who
subsequently underwent graft excision.
Ten of 17 (59%) patients managed with graft retention
relapsed and 7 had multiple relapses (range 1e5). Four died
during their ﬁrst relapse. The median time to ﬁrst relapse
was 40 months (range 0e98) and subsequent relapses 31
months (range 8e117). Four patients had positive cultures
during a relapse (Table 3). All organisms cultured during
relapse were different from the original isolates and all were
resistant to the antimicrobial therapy the patient was taking
prior to relapse. All isolates identiﬁed during follow-up were
enteric organisms. All patients with bacteraemia during
a relapse suffered at least one further episode of bacter-
aemia. Three patients relapsed with an aorto-enteric ﬁstula.
One underwent graft excision but died 2 days post-opera-
tively, one was palliated and died during the admission and
in one the haemorrhage settled shortly after admission. HeFigure 1. A Kaplan Meier plot of the survival of 17 patients diag-
nosed with an abdominal aortic graft infection who were managed
without graft explantation.
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blood transfusion and remains alive 8 years later.
Of the 17 cases, 6 (35%) subsequently had a surgical
procedure performed (Table 4). Of the 4 who underwent
complete excision of the graft, 2 subsequently relapsed and
3 died. One death was attributable to infection of the aortic
graft and this was within a day of operation. The other 2
died at 14 and 98 months after diagnosis from unrelated
causes. None of the 17 patients underwent amputation.
Complications of prolonged antimicrobial therapy included
2 cases of antibiotic associated diarrhoea including 1 case of
Clostridium difﬁcile colitis, a fractured PICC line requiring
removal, 1 Hickman line infection and 1 instance of antimi-
crobial associated hepatitis attributed to rifampicin therapy.
DISCUSSION
This report documents the treatment and outcomes an
unselected series of cases of infected abdominal aortic grafts
from a single tertiary referral centre. As there is no standard
deﬁnition of aortic graft infection, a deﬁnition was used that
included cases in which there was either clear microbiolog-
ical evidence of infection and/or clear radiological evidence.
These elements are included in the Centre of Disease Control
surveillance deﬁnition of deep surgical site infection but this
was modiﬁed in 2 ways. Firstly the CDC deﬁnition excludes
cases presenting more than 12 months after surgery which is
inappropriate in this setting as many patients present after
the ﬁrst year with clear evidence of infection. Secondly the
CDC criteria allows inclusion of cases in whom the sole
criteria is diagnosis by the attending surgeon; which we
considered insufﬁcient evidence of infection when reporting
outcomes after treatment.15
The cohort includes mainly patients with intracavitary
infection and the presentation was most commonly due to
symptoms of infection rather than haemorrhage. The rela-
tively lowratesof infectionarising in the groin reﬂectsboth the
institutional bias towards aortobiiliac grafts, rather than aor-
tobifemoral grafts for occlusive disease and that the majority
developed infection well outside the post-operative period.
The rate of graft infection cannot be estimated from this study
without knowledge of the numbers of grafts inserted. In
addition a number of cases included in this study had their
graft inserted at other centres outside our catchment area.
The decision regarding management strategy was made
by a multidisciplinary team with the informed consent of theTable 5. Series of patients managed conservatively.
Series Year N Sur
Ghosn17 1983 13 10/
(att
Morris10 1994 10 7/1
Gordon15 1994 11 treated with
intensive antibiotics
9/1
Pistolese16 1997 4 2/4
Roy8 2000 5 5/5
Calligaro9 2003 9 7/9
Hart4 2005 15 Sur
Current series 2012 17 7/1patient and most patients were offered graft retention as the
favoured strategy. A key consideration in choosing the initial
management strategy was the presence of a major hae-
morrhage from an aorto-enteric ﬁstula. This was present in
only 1 of 18 patients at presentation and inﬂuenced the
subsequent clinical approach. The treating team’s decision
for graft retention at the time of the acute presentation was
based on the view that for the particular patient, up-front
mortality of excision potentially outweighed the risks of
long-term antimicrobial therapy and risk of relapse.
Treatment with graft retention consisted of the minimum
surgery required for drainage, debridement of infected
tissue, washout of the infected area with an antiseptic
iodine solution and repair of the graft to arrest and prevent
haemorrhage. This is combined with high dose intravenous
antimicrobial therapy for 6 weeks followed by lifelong
suppressive oral antimicrobial therapy. Further operative
intervention occurred during follow-up due to a develop-
ment in the clinical course, such as relapse or intolerance of
long-term antimicrobial therapy.
All patients survived their initial admission and at least 30
days. Fifteen patients (94%) survived at least 6months.This is
consistent with survival reported in other series of cases
managed with graft retention (Table 5) and suggests that this
approach is a reasonable alternative in the short term for
those unable or unwilling to undergo major surgery.4,8e
10,16,17 It also suggests that with intensive antibiotics, even
relatively virulent organisms such as gramnegative bacilli and
particularly P. aeruginosa can be suppressed. The treatment
strategy in each reported cohort of patients with an infected
aortic graft varies due to the absence of guidelines and the
complex heterogeneity of the illness. Our strategy was
consistent with many others in using prolonged intravenous
antimicrobial therapy followed by lifelong oral therapy.8,15,16
It differed from some others who used irrigation in addition
to systemic antimicrobial therapy.9,10,16 Irrigation was not
employed in our cohort as most patients responded to
intravenous therapy alone, and due to the potential for
superinfection of the graft through the irrigated ﬂuid.
These results have a comparable long-term outcome to
those treated with graft excision, but graft explantation had
high perioperative mortality from 8% to 40%.3e7,18,19
Although management with graft retention and intensive
antimicrobials has morbidity associated with long-term
antimicrobials and disease recurrence, there may well bevival Follow-up
13
ributable mortality)
Mean 77 months
0 Median 61 months
1 Median/Mean not reported.
6/9 survivors >48 months.
Median 21 months
Median 32 months
Mean 91 months
vival numbers not reported Mean survival 28 months
7 Mean 57 months Median
survival 41 months
M.J. Maze et al. 377a lower short term mortality with this approach. Graft
explantation was thought to be the most appropriate
further management in 4 (24%) indicating that graft
retention was not the ﬁnal strategy for all those in whom it
was attempted and that the perceived risks and beneﬁts of
surgery were constantly re-evaluated.
There are no deﬁnitive studies on the duration of intra-
venous or oral antimicrobial therapy. Initial intravenous
treatment was for 4e6 weeks in keeping with usual practice
for other intravascular infections such as bacterial endo-
carditis. There is no data on the value of follow-on oral
antimicrobial; however in this series 3 of 4 patients who did
not receive lifelong antimicrobial therapy relapsed, even
though the entire infected prosthesis had been removed in
two. This suggests that prolonged antimicrobial therapy may
be of value despite debridement of all potentially infected
tissue adjacent to the graft. Prolonged antimicrobial therapy
was well tolerated as few complications due to antimicrobial
therapy or intravenous access were found. This is in keeping
with the report from Baddour et al. that showed excellent
tolerability of long-term antimicrobial therapy in a larger
group of patients with a variety of vascular infections.20
Despite ongoing antimicrobial therapy, graft retention
was associated with a substantial risk of relapse and carried
a high mortality during this ﬁrst relapse. The major causes of
death were sepsis and haemorrhage. We were unable to
detect a difference in chance of relapse due to antimicrobial
choice, but this may reﬂect the small size and heterogeneity
of the cohort. For those who survived their ﬁrst relapse,
however, the median survival was still 31 months, which in
this group of elderly patients with substantial co-morbidity
is surprisingly favourable.
Those who relapsed with bacteraemia proved to be the
most challenging group to manage conservatively. They
usually suffered multiple bacteraemic relapses which were
probably due to aorto-enteric erosion.
The patient who ﬁrst presented with an aorto-enteric
ﬁstula was managed conservatively due to multiple co-
morbidities. The most important of these were myelodys-
plasia, with intermittent thrombocytopenia and neu-
tropenia, and recurrent locally advanced squamous cell
carcinoma of the pinna. Surprisingly despite relapsing 4
times he survived 14 months with long-term self adminis-
tered home intravenous antimicrobial therapy.
Relapses that were not caused by either haemorrhage or
bacteraemia, were primarily episodes of fever that were
attributed to the known infected graft on clinical or radio-
graphic grounds by the treating doctors. It is possible that
this was inappropriate in some cases and the true number
of relapses over estimated. The median of 4 total inpatient
days for these hospital admissions indicates that most
relapses could be treated with only brief hospitalisation and
subsequent intravenous antimicrobial therapy in the home.
There was a major difference between the organisms iso-
lated at ﬁrst diagnosis and relapse. At diagnosis there were
similar proportions of grampositive cocci normally resident on
the skin and enteric organisms. Of the grampositive organisms
only 2 were diagnosed in the early post-operative period (4months) suggesting they were implanted at the time of
surgery. The organisms isolated from patients presenting later
are likely to have caused infection by haematogenous seeding
of gram positive skin organisms, or direct extension from the
bowel. This contrasts with older series where coagulase
negative staphylococci were more common, but is similar to
recent reports on the causative organisms of infected endo-
vascular aneurysm repairs.8,16,21 This may reﬂect a changing
pattern of disease. Relatively virulent organisms, particularly
gram negative bacilli have previously been associated with
higher rates on complications and recurrent sepsis.22,23 In our
series, the organism initially isolated did not appear to predict
survival or, using our broad deﬁnition, relapse.
In contrast to the organisms found at diagnosis, the
organisms causing sepsis at the time of relapse were
a mixture of enterococci, multidrug resistant gram negative
bacilli and yeasts. All but one of these came from patients in
whom enteric organisms had been previously isolated,
although the particular isolate could not have been predicted
from the clinical syndrome. The cause of this is likely to be
development of a resistant gut microbiome and ongoing
exposure of the graft to the gut ﬂora.24 The increasingly drug
resistant nature of these isolates emphasises the importance
of blood and tissue cultures to guide antimicrobial therapy
and suggests that empiric therapy should cover these path-
ogens. However, serial breakthrough bacteraemia suggests
that lifelong antimicrobial therapy with broad spectrum
agents will serve only to promote development of increas-
ingly resistant organisms in patients suffering repeat bacterial
sepsis due to aortic graft infection, and a subsequent bacterial
sepsis should prompt review of the conservative strategy.24
Conclusions from this study are tempered by several
limitations. Firstly much of the data was retrospectively
collected. Secondly, while the cohort is relatively large for
published series on conservative management, it is a small
group when compared to reports of patients managed with
graft excision. This is particularly important, as aortic graft
infection is a complex condition and individual variation can
be expected to have a substantial effect. The low numbers
of patients presenting with aorto-enteric ﬁstulae and the
absence of those with other acutely life-threatening hae-
morrhagic complications means caution is needed applying
these results to that group.
CONCLUSION
When graft retention is chosen as an initial strategy for the
management of an infected aortic graft, a low early mortality
and median survival of 41 months is possible but more than
half will relapse and may require surgery. Empiric therapy
should cover both skin and enteric organisms, even for those
presenting outside the immediate post-operative period.
Lifelong antimicrobial therapy should be recommended for
all patients not undergoing graft explantation. Culture of
tissue and blood is essential in guiding antimicrobial therapy.
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APPENDIX 1. CHARACTERISTICS, MANAGEMENT AND OUTCOMES OF PATIENTS TREATED FOR AORTIC GRAFT INFECTION.
Patient
characteristics
Infection
characteristics
Management Outcomes
Age Co-morbidities Graft type Presentation Where Timing Initial
isolate
Initial antimicrobial Duration Subsequent
antimicrobial
Operation
at diagnosis
Operation
subsequent
Survival
(Months)
Attributable
mortality
Relapses Antibiotic
complications
1 63 COPD, Cancer Aortobiiliac
Dacron
Fever/abdominal
pain
Intracavitary Late Streptococcus
intermedius/
gram positive
anaerobic
coccus
Ertapenem 6 weeks Amoxicilline
Clavulanate
þ Ciproﬂoxacin
Nil Nil 41 No 0
2 74 COPD Tube Dacron Septic emboli Intracavitary Late Alpha
haemolytic
streptococcus
Penicillin
þ Gentamicin
6 weeks Penicillin Nil Explantation and
Extra-anatomic bypass
6 Yes 1
3 63 Nil Aortobifemoral
Dacron
False
aneurysm
Intracavitary Late Streptococcus
pyogenes
Penicillin
þ Rifampicin
6 weeks Nil Drainage Nil 195 N/A 1 Line infection
4 85 IBD Tube Dacron Fever/
abdominal
pain
Intracavitary Late Escherichia
coli
Piperacillin
eTazobactam
6 weeks Amoxicillin
eClavulanate
þ Ciproﬂoxacin
Nil Nil 40 Yes 2 Diarrhoea
5 77 IHD, Cancer,
CRF
Aortobiiliac
Dacron
Aorto-enteric
ﬁstula
Intracavitary Late Fusobacterium
necrophrum/
Bacteroides
fragilis
Ertapenem 6 weeks Amoxicillin
eClavulanate
þ Ciproﬂoxacin
Nil Nil 14 Yes 4
6 82 IHD, COPD Aortobiiliac
Dacron
Fever Intracavitary Late Staphylococcus
aureus
Flucloxacillin 6 weeks Flucloxacillin Nil Nil 45 No 0
7 73 COPD, Cancer Aortobifemoral
Dacron
Sinus Intracavitary Late Nil Cefuroxime/
Metronidazole
5 days Augmentin Drainage Nil 50 Yes 2
8 72 COPD Tube Dacron Wound
breakdown/
false aneurysm
Extracavitary Late Staphylococcus
aureus
Flucloxacillin
þ Rifampicin
6 weeks Flucloxacillin
þ Rifampacin#
Drainage Explantation and
anatomic bypass
98 No 0
9 75 Nil Tube
Unknown
material
Abdominal
pain/fever
Intracavitary Late Staphylococcus
aureus
Cephazolin
þ Rifampicin
6 weeks Flucloxacillin Drainage Nil 47* N/A 0
10 64 IHD, COPD,
Cancer
Aortobifemoral
Dacron
False
aneurysm
Extracavitary Late Pseudomonas
aeruginosa
Amoxicillin
eClavulanate
3 days Amoxicillin
eClavulanate#
Complete excision/
Patch insertion
Patch removal and
aortoplasty
128* N/A 1
11 64 IHD, COPD,
Diabetes
Aortobifemoral
Unknown
material
Fever/
abdominal
pain
Intracavitary Late Klebsiella
oxytoca/
Escherichia coli
Cefuroxime and
Metronidazole
4 weeks Nil Nil Nil 1 Yes 1
12 75 CRF Aortobiiliac
Dacron
Fever/
abdominal
pain
Intracavitary Late Nil Ceftriaxone 2 weeks Amoxicillin
eClavulanate
Nil Explantation and
anatomic bypass
14 No 2
13 64 ILD,
Polymyositis
Aortobifemoral
Dacron
Fever/abdominal
pain
Intracavitary Late Streptococcus
intermedius
Cephazolin 6 weeks Amoxicillin
eClavulanate
Nil Nil 63 Yes 0 C. difﬁcile
14 66 COPD Aortobifemoral
Dacron
Wound
breakdown/
Sinus
Extracavitary Early Group B
Streptococcus and
Staphylococcus
aureus
Cephazolin 6 weeks Amoxicillin
eClavulanate
Nil Nil 23* N/A 0
15 79 IHD, Diabetes,
CVA
Tube Dacron Fever/
abdominal
pain
Intracavitary Early Mixed aerobic
ﬂora
Ertapenem 6 weeks Amoxicillin
eClavulanate
Drainage Nil 11* N/A 0
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